SEC Form 4 filed by Pluristem Therapeutics, Inc.
$PSTI
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
Waives Option to Classify Board Under Maryland Law Independence Realty Trust, Inc. (NYSE:IRT) ("IRT" or the "Company") today announced the appointment of Craig Macnab to its Board of Directors (the "Board"), effective February 29, 2024. Mr. Macnab brings over 20 years of experience to IRT's Board after serving in various executive and board roles in the REIT industry, including most recently as CEO of National Retail Properties, Inc. (NYSE:NNN) for 13 years. Mr. Macnab's appointment increases the size of IRT's Board to 10 members, including 8 independent directors. In connection with this announcement, the Company has entered into a cooperation agreement with Argosy-Lionbridge Management,
HAIFA, Israel, July 25, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri" or the "Company") (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, today issued an update to its shareholders from its Chief Executive Officer and President Yaky Yanay. Pluri: One simple, short word of Greek origin that encapsulates the strategic evolution for our Company. This is our new name. Today, I am proud to share the vision of Pluri: to help pioneer a biotech revolution to create a range of next-generation cell-based products that improve human wellbeing, increase sustainability, and advance solutions to humanity's greatest challenges. In early 2021,
As of July 26, 2022, Pluri's stock will trade under the symbol PLURThe new name reflects the Company's strategy to leverage its innovative 3D cell-based technology to a range of fields, developing cell-based products that address various life challenges, while also promoting global wellbeing and sustainabilityVisit our new Company website: www.pluri-biotech.com HAIFA, Israel, July 25, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri" or the "Company"), a leading biotechnology company, today announced its name change (NASDAQ:PSTI), reflecting a broader strategy of leveraging its 3D cell expansion technology to develop innovative cell-based products that can be harness
8-K - Pluri Inc. (0001158780) (Filer)
D - Pluri Inc. (0001158780) (Filer)
8-K - Pluri Inc. (0001158780) (Filer)
Waives Option to Classify Board Under Maryland Law Independence Realty Trust, Inc. (NYSE:IRT) ("IRT" or the "Company") today announced the appointment of Craig Macnab to its Board of Directors (the "Board"), effective February 29, 2024. Mr. Macnab brings over 20 years of experience to IRT's Board after serving in various executive and board roles in the REIT industry, including most recently as CEO of National Retail Properties, Inc. (NYSE:NNN) for 13 years. Mr. Macnab's appointment increases the size of IRT's Board to 10 members, including 8 independent directors. In connection with this announcement, the Company has entered into a cooperation agreement with Argosy-Lionbridge Management,
HAIFA, Israel, March 08, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE: PSTI), a leading biotechnology company ("Pluristem"), and Tnuva Group ("Tnuva Group" or "Tnuva"), Israel's largest food producer, today jointly announced the appointment of Eyal Rosenthal as Chief Executive Officer of their landmark joint venture to develop, manufacture and commercialize cultured meat. Eyal Rosenthal, Chief Executive Officer(photo credit: Jim Vetter) Mr. Rosenthal is a seasoned entrepreneur and visionary leader in the agritech and food tech industries, serving until recently as venture partner and head of Israeli operations at Finistere Ventures, a pioneering global ventu
HAIFA, Israel, July 19, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE: PSTI), a leading biotechnology company, today announced the Board of Director appointments of Prof. Varda Shalev, a physician, medical researcher, and Professor of Medicine at the Tel Aviv University's School of Public Health, and Mr. Doron Birger, a high-tech industry executive with a background in bringing groundbreaking products to market. Prof. Shalev has more than 30 years of experience working in clinical environments and research settings at the intersection of health and technology. She was the founder and Chief Executive Officer of the KSM Institute of Research and Innovation and Mac
Alliance Global Partners initiated coverage of Pluristem Therapeutics with a rating of Buy and set a new price target of $12.50
4 - Pluri Inc. (0001158780) (Issuer)
4 - Pluri Inc. (0001158780) (Issuer)
4 - PLURISTEM THERAPEUTICS INC (0001158780) (Issuer)
SC 13D - Pluri Inc. (0001158780) (Subject)
SC 13G - PLURISTEM THERAPEUTICS INC (0001158780) (Subject)
SC 13G/A - PLURISTEM THERAPEUTICS INC (0001158780) (Subject)
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Pluristem Therapeutics Changes its Name To Pluri Pluristem Therapeutics Inc (NASDAQ:PSTI) will be renamed Pluri Inc and start trading on NASDAQ under the ticker PLUR from July 26. The change reflects a broader strategy of leveraging its 3D cell expansion technology to develop cell-based products that can be harnessed for various fields beyond medicine. AstraZeneca's Enhertu Under FDA Priority Review For HER2-Low Metastatic Breast Cancer The FDA has accepted AstraZeneca Plc (NASDAQ:AZN) and Daiichi Sankyo's (OTC:DSNKY) supplemental application seeking approval for Enhertu (trastuzumab derux
Gainers Hanger (NYSE:HNGR) stock moved upwards by 27.1% to $18.75 during Thursday's after-market session. The company's market cap stands at $731.7 million. Biophytis (NASDAQ:BPTS) stock rose 13.92% to $0.99. The company's market cap stands at $16.2 million. IsoPlexis (NASDAQ:ISO) shares rose 12.31% to $3.74. The company's market cap stands at $146.1 million. Delcath Systems (NASDAQ:DCTH) shares increased by 11.13% to $4.89. The company's market cap stands at $38.6 million. Plus Therapeutics (NASDAQ:PSTV) shares moved upwards by 10.0% to $0.55. The company's market cap stands at $12.2 million. The company's, Q2 earnings came out today. Vallon Pharmaceuticals (NASDAQ:VLON) stock increas
Alliance Global Partners analyst James Molloy maintains Pluristem Therapeutics (NASDAQ:PSTI) with a Buy and lowers the price target from $9.5 to $4.